Dementing Illness and Complementary and Alternative Medicine

  • R. McCarney
  • J. Warner


Dementia is a common illness in older people and has major implications for individuals with the disease, their carers and society. The recent development of conventional therapies for dementia has spurred interest in all forms of treatment and led to a new era of therapeutic optimism. This chapter outlines the clinical and epidemiological features of the principal types of dementia and reviews the evidence base for CAM treatments.


Lewy Body Dementia With Lewy Body Vascular Dementia Cholinesterase Inhibitor Music Therapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Ott, Brian R, Owens NJ (1998) Complementary and alternative medicines for Alzheimer’s disease. Journal of Geriatric Psychiatry & Neurology 11 (4): 163–173.Google Scholar
  2. 2.
    Birks JS, Melzer D, Beppu H. Donepezil for mild and moderate Alzheimer’s disease (Cochrane Review). In: The Cochrane Library, Issue 2 2002. Oxford: Update Software.Google Scholar
  3. 3.
    Birks J, Grimley Evans J, Iakovidou V, Tsolaki M (2002) Rivastigmine for Alzheimer’s disease (Cochrane Review). In: The Cochrane Library, Issue 2 2002. Oxford: Update Software.Google Scholar
  4. 4.
    Wilcock G, Lilienfield S, Gaens E (2000) Efficacy and safety of galantamine in patients with mild to moderate Alzheimer’s disease: multicentre randomised controlled trial. British Medical Journal 321: 1–7.CrossRefGoogle Scholar
  5. 5.
    World Health Organisation (1993) ICD-10: International Statistical Classification of Diseases and Related Health Problems (10th Revision). WHO, Geneva.Google Scholar
  6. 6.
    Crook T, Bartus RT, Ferris SH, et al. (1986) Age associated memory impairment: proposed diagnostic criteria and measures of clinical change. Developmental Neuropsychology 2: 261–76CrossRefGoogle Scholar
  7. 7.
    Hardy J (1991) Molecular classification of Alzheimer’s disease. Lancet 337: 1342–1343.Google Scholar
  8. 8.
    Lobo A, Launer LJ, Fratiglioni L et al. (2000) Prevalence of dementia and major subtypes in Europe: A collaborative study of population-based cohorts. Neurology 54: 54–9.Google Scholar
  9. 9.
    Prince M (2000) The epidemiology of Alzheimer’s disease. In: O’Brien, Ames and Burns (eds) Dementia ( 2nd edition ). Arnold, London.Google Scholar
  10. 10.
    Perry RH, Irving D, Blessed G, et al. (1989) Senile dementia of Lewy body type and spectrum of Lewy body disease. Lancet 1: 1088.PubMedCrossRefGoogle Scholar
  11. 11.
    Finkel SL (1998) Signs of behavioural and psychological symptoms of dementia. Clinician 16: 33–42.Google Scholar
  12. 12.
    McKeith IG, Galasko D, Kosaka K et al. (1996) Consensus guidelines for the clinical and pathological diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB International workshop. Neurology 47: 1113–1124.PubMedCrossRefGoogle Scholar
  13. 13.
    Foster S, Tyler VE (1999) Tyler’s honest herbal: a sensible guide to the use of herbs and related remedies ( 4th edition ). The Haworth Herbal Press, New York.Google Scholar
  14. 14.
    Schilcher H (1988) Zeitschrift für Phytotherapie 9:119–127. Comment in: Foster S, Tyler VE (1999) p184.Google Scholar
  15. 15.
    van Beek T, Bombardelli E, Morazzoni P, Peterlongo F (1998) Ginkgo biloba L. Fitoterapia LXIX (3): 195–244.Google Scholar
  16. 16.
    Oken B, Storzbach D, Kaye 1 (1998) The efficacy of Ginkgo biloba on cognitive function in Alzheimer disease. Archives of Neurology 55: 1409–1415.Google Scholar
  17. 17.
    Ernst E, Pittler M (1999) Ginkgo biloba for dementia: A systematic review of double-blind, placebo-controlled trials. Clinical Drug Investigations 17 (4): 301–308.CrossRefGoogle Scholar
  18. 18.
    Wettstein A (2000) Cholinesterase inhibitors and Ginkgo extracts-are they comparable in the treatment of dementia? Comparison of published placebo-controlled efficacy studies of at least six months’ duration. Phytomedicine 6 (6): 393–401.PubMedCrossRefGoogle Scholar
  19. 19.
    Le Bars P, Kieser M, Itil K (2000) A 26-week analysis of a double-blind, placebo-controlled trial of the ginkgo biloba extract EGb 76l® in dementia. Dementia and Geriatric Cognitive Disorders 11 (4): 230–7.PubMedCrossRefGoogle Scholar
  20. 20.
    Le Bars P, Katz M, Berman N, et al (1997) A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. JAMA 278: 1327–1332.PubMedCrossRefGoogle Scholar
  21. 21.
    Kayne S (2001) Ginkgo biloba: potential concern. Good Clinical Practice Journal 8 (11): 8–10.Google Scholar
  22. 22.
    Allain H, Schuck S, Lebreton S, et al. (1999) Aminotransferase levels and silymarin in de novo tacrine-treated patients with Alzheimer’s disease. Dementia and Geriatric Cognitive Disorders 10 (3): 181–5.PubMedCrossRefGoogle Scholar
  23. 23.
    Itoh T, Shimada Y, Terasawa K (1999) Efficacy of Choto-san on vascular dementia and the protective effect of the hooks and stems of Uncaria sinensis on glutamate-induced neuronal death. Mechanisms of Ageing and Development 111 (2–3): 155–73.PubMedCrossRefGoogle Scholar
  24. 24.
    Arai H, Suzuki T, Sasaki H, et al (2000). A new interventional strategy for Alzheimer’s disease by Japanese herbal medicine (Japanese) Japanese Journal of Geriatrics 37 (3): 212–5.PubMedGoogle Scholar
  25. 25.
    Chen K, Chen KJ, Zhou WQ (1997) Clinical study of effect of yizhi capsule on senile vascular dementia (Chinese). Chung-Kuo Chung Hsi i Chieh Ho Tsa Chih 17 (7): 393–7.PubMedGoogle Scholar
  26. 26.
    Xu H, Shao N, Cui D, et al. (2000) A clinical study of yi zhi capsules in prevention of vascular dementia. Journal of Traditional Chinese Medicine. 20 (1): 10–3.PubMedGoogle Scholar
  27. 27.
    Smallwood J, Brown R, Coulter F, et al. (2001) Aromatherapy and behaviour disturbances in dementia: a randomized controlled trial. International Journal of Geriatric Psychiatry 16: 1010–1013.PubMedCrossRefGoogle Scholar
  28. 28.
    Smallwood J, Irvine E, Coulter F, Connery H. (2001) Psychometric evaluation of a short observational tool for small-scale research projects in dementia. International Journal of Geriatric Psychiatry 16: 288–292.PubMedCrossRefGoogle Scholar
  29. 30.
    Holmes C, Hopkins V, Hensford C, et al. (2000) Lavender oil as a treatment for agitated behaviour in severe dementia: a placebo controlled study. International Journal of Psychogeriatrics 13 (suppl 2): pp 277.Google Scholar
  30. 31.
    Brooker DJ, Snape M, Johnson E, et al. (1997) Single case evaluation of the effects of aromatherapy and massage on disturbed behaviour in severe dementia. British Journal of Clinical Psychology 36 (Pt 2): 287–96.PubMedCrossRefGoogle Scholar
  31. 32.
    Kim EJ, Buschmann MT (1999) The effect of expressive physical touch on patients with dementia. International Journal of Nursing Studies 36 (3): 235–43.PubMedCrossRefGoogle Scholar
  32. 33.
    Opie J, Rosewarne R, O’Connor D W (1999) The efficacy of psychosocial approaches to behaviour disorders in dementia: a systematic literature review. Australian and New Zealand Journal of Psychiatry 33 (6): 789–799.PubMedCrossRefGoogle Scholar
  33. 34.
    Vink AC, Bruinsma MS, Scholten R. (2002) Music therapy in the care of people with dementia (Protocol for a Cochrane Review). In: The Cochrane Library, Issue 2,2002. Oxford: Update Software.Koger SM, Brotons M ( 2000 ) Music therapy for dementia symptoms. Cochrane Database of Systematic Reviews.Google Scholar
  34. 35.
    Koger S M, Chapin K, Brotons M (1999) Is music therapy an effective intervention for dementia: a meta-analytic review of literature. Journal of Music Therapy 36 (1): 2–15.PubMedGoogle Scholar
  35. 36.
    Geng J (1999) Treatment of 50 cases of senile dementia by acupuncture combined with inhalation of herbal drugs and oxygen. Journal of Traditional Chinese Medicine 19 (4): 287–9.PubMedGoogle Scholar
  36. 37.
    Xudong G (1999) The influence of acupuncture modalities on the treatment of senile dementia: a brief review. American Journal of Acupuncture 24: 105–109.Google Scholar
  37. 38.
    Liu HA, Hou DF, Diao ZY, Wang Y (1997) Observation on the clinical curative effects of turbit clearing and intelligence-improving acupuncture therapy on vascular dementia and the study onits mechanisms. Chinese Acupuncture and Moxibustion 17 (9): 521–525.Google Scholar
  38. 39.
    Lai XS (1997) Observation on curative effects of senile vascular dementia treated by acupuncture. Chinese Acupuncture and Moxibustion 17 (4): 201–202.Google Scholar
  39. 40.
    Jiang ZY, Li CD, Li YK (1999) Treatment of vascular dementia with scalp acupuncture. International Journal of Clinical Acupuncture 10 (1): 15–21.Google Scholar
  40. 41.
    Zhang AR, Pan ZW, Lou F (1995) Effect of acupuncturing houxi and shenmen in treating cerebral traumatic dementia (Chinese). Chung-Kuo Chung Hsi i Chieh Ho Tsa Chih 15 (9): 519–21.PubMedGoogle Scholar
  41. 42.
    Emerson Lombardo NB, Vehvilainen L, Ooi WL et al. (2000) Acupuncture to treat anxiety and depression in Alzheimer’s disease and vascular dementia: a pilot feasibility and effectiveness trial. Conference proceedings World Alzheimer Congress; 9–13 July, Washington DC.Google Scholar
  42. 43.
    Vatassery GT, Bauer T, Dysken M (1999) High doses of vitamin E in the treatment of disorders of the central nervous system in the aged. American Journal of Clinical Nutrition 70 (5): 793–801.Google Scholar
  43. 44.
    Launer LJ, Kalmijn S (1998) Anti-oxidants and cognitive function: a review of clinical and epidemiologic studies. Journal of Neural Transmission Supplementum 53: 1–8.PubMedCrossRefGoogle Scholar
  44. 45.
    Grundman M (2000) Vitamin E and Alzheimer disease: the basis for additional clinical trials. American Journal of Clinical Nutrition 71 (2): 6305–6365.Google Scholar
  45. 46.
    Praticò D, Delanty N (2000) Oxidative injury in diseases of the central nervous system: focus on Alzheimer’s disease. American Journal of Medicine 109 (7): 577–85.PubMedCrossRefGoogle Scholar
  46. 47.
    Sano M, Ernesto C, Thomas RG, et al. (1997) A controlled trial of selegiline, alpha-tocopherol, or both as a treatment for Alzheimer’s disease. New England Journal of Medicine 336: 1216–1222.PubMedCrossRefGoogle Scholar
  47. 48.
    Drachman DA, Leber P (1997) Treatment of Alzheimer’s disease: searching for a breakthrough, settling for less. New England Journal of Medicine 336: 1245–1247.PubMedCrossRefGoogle Scholar
  48. 49.
    Gutzmann H, Hadler D (1998) Sustained efficacy and safety of idebenone in the treatment of Alzheimer’s disease: update on a 2-year double-blind multicentre study. Journal Neural Transmission 54 (suppl): 301–310.Google Scholar
  49. 50.
    Freeman MP (2000) Omega-3 fatty acids in psychiatry: a review. Annals of Clinical Psychiatry 12 (3): 159–65.PubMedGoogle Scholar
  50. 51.
    Gillette-Guyonnet S, Nourhashémi F, Andrieu S, et al. (2000) Weight loss in Alzheimer disease. American Journal of Clinical Nutrition 71 (suppl): 6375–425.Google Scholar
  51. 52.
    Carver AD, Dobson AM (1995) Effects of dietary supplementation of elderly demented hospital residents. Journal of Human Nutrition and Dietetics 8 (6): 389–394.CrossRefGoogle Scholar
  52. 53.
    Chandra RK (2001) Effect of vitamin and trace-element supplementation on cognitive function in elderly subjects. Nutrition 17 (9): 709–12.PubMedCrossRefGoogle Scholar
  53. 54.
    McGaffigan, S., Bliwise, DL. (1997) The treatment of sundowning: A selective review of pharmacological and nonpharmacological studies. Drugs and Aging, 10 (1), 10–17.PubMedCrossRefGoogle Scholar
  54. 55.
    Rindlinsbacher P and Hopkins RW (1992) An investigation of the sundowning syndrome. International Journal of Geriatric Psychiatry, 7, 15–23.CrossRefGoogle Scholar
  55. 56.
    LewyAJ. Sack RL. Blood ML. Bauer VK. Cutler NL. Thomas KH. (1995) Melatonin marks circadian period position and resets the endogenous circadian pacemaker in humans. Ciba Foundation Symposium. 183: 303–17; discussion 317–21.Google Scholar
  56. 57.
    Uchida K. Okamoto N. Ohara K. Morita Y. (1996) Daily rhythm of serum melatonin in patients with dementia of the degenerate type. Brain Research. 717 (1–2): 154–9.PubMedCrossRefGoogle Scholar
  57. 58.
    Haffmans PM, Sival RC, Lucius SA, et al. (2001) Bright light therapy and melatonin in motor restless behaviour in dementia: a placebo-controlled study. International Journal of Geriatric Psychiatry 16 (1): 106–10.PubMedCrossRefGoogle Scholar
  58. 59.
    DeKosky ST, et al. (2000) Ginkgo Biloba Prevention Trial in Older Individuals. Google Scholar
  59. 60.
    Nourhashémi F, Gillette-Guyonnet S,Andrieu S, et al. (2000) Alzheimer disease: protective factors. American Journal of Clinical Nutrition 71 (2): 643S - 649S.PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2003

Authors and Affiliations

  • R. McCarney
  • J. Warner

There are no affiliations available

Personalised recommendations